Data on Delcath’s PHP Therapy presented at CIRSE 2018
24 sept. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
23 août 2018 11h14 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
21 août 2018 08h52 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
20 août 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Amends Phase 3 Ocular Melanoma Trial Protocol
27 juil. 2018 08h00 HE
|
Delcath Systems, Inc.
Revision to Nonrandomized (Single Arm) Study Reduces Trial Size Enrollment Requirement Enrollment Anticipated to be Completed by First Half 2019 NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) --...
Delcath Systems to Present at the 8th Annual LD Micro Invitational
29 mai 2018 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced...
Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
22 mai 2018 08h15 HE
|
Delcath Systems, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to...
Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
16 mai 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology
14 mai 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...